natgillin/translations-raw huggingface dataset:
said knitted tubular fabric (1) has a heat adhesive material (4) applied under heat onto at least one portion of a surface of the fabric so as to stabilize the fabric itself. 
rezanje cjevaste tkanine (1) na koju je toplinsko adhezivni materijal (4) primijenjen, tako da se dobije otvoreni komad (9) tkanine.
Dimethyl fumarate or monomethyl fumarate for use in treating multiple sclerosis, wherein the dimethyl fumarate or monomethyl fumarate is to be orally administered to a subject in need of treatment for multiple sclerosis at a dose of about 480 mg to about 720 mg per day. 
Dimetil fumarat ili monometil fumarat za upotrebu u liječenju multiple skleroze, naznačen time da je dimetil fumarat ili monometil fumarat jedini neuroprotektivni spoj koji se primjenjuje, i pri čemu se dimetil fumarat ili monometil fumarat oralnim putem daje osobi kojoj je potrebno liječenje multiple skleroze u dozi od 480 mg dnevno.
A composition comprising compound having a structure of Formula 8 or stereoisomer thereof or pharmaceutically acceptable salt thereof, wherein n and m are as recited in claim 1. 
Sastav sadrži tvar koja ima strukturu Formule 8 ili njen stereoizomer ili njenu farmaceutski prihvatljivu sol, pri čemu su ni m opisani u patentnom zahtjevu 1. s Å a
The immunoconjugate according to claim 1 wherein the cytotoxic agent is a maytansinoid or a derivative thereof. 
-LCDR3S je predstavljena sa SEQ ID NO: 19, i pri čemu citotoksično sredstvo je majtanzinoid.
reacting 3-nitro-N-ethoxycarbonyl-phthalimide with a glutamine ester having Formula (VIII): or an acid salt thereof in the presence of a first catalyst to form a compound of Formula (IX) or a salt, solvate, polymorph or stereoisomer thereof: and 
reakcije 3-nitro-N-etoksikarbonilftalimida s esterom glutamina Formule (VIII): [image] ili njegovom solju s kiselinom, u prisutnosti prvog katalizatora, kako bi se dobilo spoj Formule (IX) ili njegovu sol, solvat, polimorf ili stereoizomer:
A method according to claim 33, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje navedena upalna stanja i imunosne poremećaje se bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože te srca.
The organic phase is concentrated in vacuo to provide about 271.8 g (76%) of compound (d), (+/-)-3-(4-hydroxy-phenyl)-2-methoxy-propionic acid methyl ester, as an oil. 
Organsku fazu koncentrira se u vakuumu kako bi se dobilo približno 271,8 g (76 %) spoja (d), metilnog estera (+)-3-(4hidroksifenil)-2-metoksipropionske kiseline, u obliku ulja.
Figure 4 is a sectional view taken along a medium longitudinal plane of the ski boot according to the invention in a minimum-length configuration; Figure 5 is a view similar to Figure 4 of the ski boot in a maximum-length configuration. 
prikazuje presjek napravljen uzduž srednje uzdužne ravnine cipele za skijanje prema izumu u konfiguraciji minimalne duljine; slika 5 = prikazuje cipelu za skijanje sa slike 4 u konfiguraciji maksimalne duljine.
The method according to claim 1, wherein the white mineral is selected from the group consisting of a calcium carbonate-based mineral mixed with clay or talc or calcium hydroxide or calcium sulphate, a calcium carbonate-kaolin mixture, a mixture of calcium carbonate and bentonite, a mixture of natural calcium carbonate with aluminium hydroxide, magnesium hydroxide, mica or with synthetic or natural fibers, co-structures of minerals, a talc-calcium carbonate, a talc-titanium dioxide, and a calcium carbonate-titanium dioxide co-structure. 
Postupak u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je bijeli mineral mineral na bazi kalcijeva karbonata pomiješan s glinom ili talkom ili kalcijevim hidroksidom ili kalcijevim sulfatom, ili se radi o smjesama kalcijeva karbonata i kaolina ili smjesama kalcijeva karbonata i bentonita, ili smjesama prirodnog kalcijeva karbonata i aluminijeva hidroksida, magnezijeva hidroksida, tinjca ili sintetičkih ili prirodnih vlakana ili je kostruktura minerala, ponajprije kostruktura talk-kalcijeva karbonata ili talk-titanijeva dioksida ili kalcijeva karbonat-titanija dioksida.
DNA methyl transferases Cytokines and retinoids Chromatin targeted therapies, e.g. HDAC or HAT modulators 
Kromatinske ciljane terapije, npr. modulatore HDAC (modulatore histom deacetilaze) ili HAT (histon acetintransferaze) m.
Apparatus as claimed in claim 2, wherein each recess 101, 102; 101', 102') has a second wall (101b, 102b) which is opposite to, and less steeply inclined than, the wall (101a, 102a) forming the said abutment surface. 
Uredaj u skladu s patentnim zahtjevom 1, kod kojega svako od udubljenja (101, 102; 101', 102') ima drugu stijenku (101b, 102b) koje je na suprotnoj strani i nagnuta je s manjim nagibom nego što je stijenka (101a, 1024) koja čini navedenu površinu za podupiranje.
A composition comprising at least one isolated IL-23p19 antibody according to claims 1-5 and at least one pharmaceutically acceptable carrier or diluent. 
Pripravak koji sadrži najmanje jedno izolirano IL-23p19 antitijelo prema patentnim zahtjevima 1-5 i najmanje jedan farmaceutski prihvatljiv nosač 1li razrjeđivač.
Three slurries having a calcium carbonate concentration of 5 wt.-% based on the total weight of the slurry were prepared from marble micronized calcium carbonate having a particle size of 3.5, 9, and 20 µm, respectively, and a HCl insoluble content of 0.2 wt.-% based on the total weight of the calcium carbonate. 
Postupak za remineralizaciju vode koji sadrži korake: a) dobavljanje ulazne vode, te b) injektiranje plinovitog ugljik dioksida 1 mulja u ulaznu vodu, pri čemu mulj sadrži mikronizirani kalcij karbonat, gdje kalcij karbonat ima veličinu čestica od 0.1 do 100 um i HCI netopljivi sadržaj od 0.05 do 1.5 wt-% zasnovano na ukupnoj masi mikroniziranog kalcij karbonata.
a light chain sequence selected from SEQ ID NO: 15 of Figure 7 and SEQ ID NO: 69 of Figure 15. 
slijed lakog lanca kojeg se bira između SEQ ID NO: 15 na Slici 7 i SEQ ID NO: 69 na Slici 15.
Hence, in order to further imitate sugar, the sugar replacement composition according to the invention may be granulated. 
Doista, u svrhu još boljeg oponašanja šećera, sastavina koja prema ovom izumu zamjenjuje šećer može se granulirati.
represents [1] a hydrogen atom, [2] a cyano group, or [3] a halogen atom; 
R' predstavlja [1] atom vodika, [2] skupina cijano ili [3] atom halogena;
A process for the preparation of a compound of formula II in which L1 represents bromo (as claimed in Claim 4), which process comprises bromination of a compound of formula III, 
O 5. > Postupak za dobivanje spoja formule II, naznačen time da L' predstavlja bromo (prema zahtjevu 4), pri čemu postupak sadrži bromiranje spoja formule III, 6.
While significant strides have been made in this field, there remains a need in the art for effective small molecule GnRH receptor antagonists. 
Iako značajni su poduzeti koraci u ovom području tehnike, u struci i dalje postoji potreba za djelotvornim niskomolekulskim antagonistima receptora GnRH.
In vitro Average Pore 
Prosječna veličina pora (um
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a temperature that is set at 36±0.9 °C, wherein the cell culture is a continuous culture maintained at a density of 1.4x106 to 2.8x106 cells/ml, and wherein the mammalian cell is a CHO cell. The method according to claim 1 wherein the temperature is set at 36±0.5 °C, 36±0.2 °C, 36 °C or 36.5 °C. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X + 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 x 105 do 2,8 x 105 stanica/ml.
A compound having a structural Formula (III): or a salt, solvate, or ester thereof; wherein 
Spoj koji ima strukturnu formulu (III): [image] ili njegova sol, solvat ili njegov ester; naznačen time da X i Y su O;
Although this tube might be better controllable due to its ratherly rigid nature accurate positioning is only possible by a skilled physician after exposing the cervix with a vaginal tenaculum because of its size. 
Iako se s ovom cijevi može bolje upravljati zbog dosta krute prirode, točno pozicioniranje može provesti samo stručan liječnik nakon što izloži grlić maternice vaginalnom držaču zbog njegove veličine.
said treated waste water is subsequently discharged; 
- < ta obrađena otpadna voda se zatim ispušta;
A peptide consisting of the amino acid sequence according to SEQ ID No. 22. 
Peptid koji se sastoji od sekvence prema ID br.
Sugar and fat are important for the softness of ice cream and the ability to scoop frozen ice cream. 
Šećer i masnoće važni su za mekoću sladoleda i za oblikovanje zamrznutog slastičarskog sladoleda u kuglice.
with an amino of formula (III): wherein R1 represents hydrogen or C1-4 alkyl group, R2 represents hydrogen or C1-4 alkyl group, and, where appropriate, separating the enantiomers and/or diastereomers, and/or cis- and/or trans-isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
HR P20110785 T1 R! predstavlja vodik ili C,., alkil skupinu, R* predstavlja vodik ili C,., alkil skupinu, i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (1), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formulo (1).
The method of claim 5, wherein cooled N-butyl-2-cyanoacrylate is mixed with a required quantity of organic acid as a stabilizer. The method of claim 5, wherein 3-methacryloxysulpholane is placed into a container, wherein the inner surface of the container for 3-methacryloxysulpholane is preliminarily treated with sulfur dioxide as a stabilizer wherein the stabilizer comprises sulfur dioxide, said stabilizer is present in an amount no less than total 0.45 wt % and no more than total 0.55 wt % based on the total wt % of the composition. 
N-butil-2-cijanoakrilat ostatak Postupak za proizvodnju medicinskog ljepila temeljem zahtjeva 1, naznačen time da se sastojci ljepila miješaju pri čemu je tražena količina 3-metakriloksisulfolana pomiješana sa smjesom tražene količine ohlađenog N-butil-2- cijanoakrilata i tražene količine organske kiseline kao stabilizatorom te promiješane, a pri čemu se unutrašnja površina spremnika 3-metakriloksisulfolana preliminarno tretira sumpornim dioksidom kao stabilizatorom.
A composition for sustained release of a biologically active polypeptide, comprising a biocompatible polymer having the biologically active polypeptide dispersed therein so as to be present at 5% (w/w) of the weight of the composition, and sucrose dispersed therein so as to be present at 2% (w/w) of the weight of the composition, wherein the biologically active polypeptide is exendin-4; wherein the total pore volume of the composition is 0.1 mL/g or less as determined using mercury intrusion porosimetry; and wherein the composition is free from buffer and salting out salts. 
Oblik za produljeno oslobađanje biološki aktivnog polipeptida, koji obuhvaća biokompatibilni polimer u kojem je biološki aktivni polipeptid dispergiran tako da ga ima u količini od 5% (w/w) težine oblika, i saharoza je dispergirana tako da je ima u količini od 2% (w/w) težine oblika, pri čemu je biološki aktivni polipeptid eksendin-4; pri čemu je ukupni volumen pora oblika 0,1 ml/g ili manje što je utvrđeno porozimetrijom utiskivanja žive; i pri čemu u obliku nema pufera i soli za isoljavanje.
enzymatically reacting, using the isoprenoid transferase, the expressed protein with at least one isosubstrate having a first functional group (FG1), thereby producing a functionalized protein; 
(b) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu eksprimirano antitijelo s najmanje jednim izosupstratom koji ima prvu funkcionalnu skupinu (FG1), čime se proizvodi funkcionalizirano antitijelo;
A solid system in the form of a tablet or capsule for the modified release and oral administration of one or more active ingredients, including a polymeric matrix comprising an ionic polymer which is hyaluronic acid in the form of free acid with a weighted-average molecular weight ranging from 100 to 100,000 Daltons (Da) measured with SEC-MALLS technique, a non-ionic polymer which jellifies in contact with a liquid, and an active ingredient dispersed in the polymeric matrix. 
PATENTNI ZAHTJEVI Čvrsti sustav u obliku tablete ili kapsule za modificirano oslobađanje i oralnu primjenu jednog ili više aktivnih sastojaka, uključujući polimerni matriks koji sadrži jonski polimer koji je hijaluronska kiselina u obliku slobodne kiseline sa ponderiranom prosječnom molekulskom masom u opsegu od 100 do 100,000 Daltona (Da) izmjerenom sa SECMALLS tehnikom, neionski polimer koji se pretvara u želatinoznu masu u kontaktu sa tečnošću i aktivni sastojak dispergovan u polimernom matriksu.
The method of claim 7, wherein the DNA marker is amplified and detected using Real Time PCR methodology. 
Metoda prema patentnom zahtjevu 4, naznačena time da je DNA marker umnožen i detektiran upotrebom metodologije PCR-a u realnom vremenu (Real Time PCR).
A dispenser according to claim 1, further comprising a dose counter for indicating a number of actuations of the dispenser corresponding to a number of doses dispensed from the substance source, or a number of doses remaining in the substance source. 
Dispenzer sukladno bilo kojem od prethodnih zahtjeva, koji nadalje sadrži brojač doza za ukazivanje na broj aktivacija dispenzera koji odgovara broju doza distribuiranih iz izvora supstance, ili broja doza koje preostaju u izvoru supstance.
use of a compound of the present invention for the preparation of a medicament for inhibiting tumor/cancer growth both in vitro and in vivo; 
Uporaba formule sukladno patentnom zahtjevu 1, radi pripreme medikamenta za spriječavanje proliferacije stanica tumora/raka kod pojedinca.
Q represents -ORc, -OCORc, -NRcRd, or a halogen atom; Rc and Rd, which may be the same or different, each represent a hydrogen atom or a C1-5 alkyl group; and R1, R2, R3, R4, Z', Q, and W' may have protecting group(s) required for the synthesis]. 
Q predstavlja -ORc, -OCORc, -NRcRd ili atom halogena; svaki od Rc i Rd, koji mogu biti isti ili različiti, predstavlja atom vodika ili C1-5 alkilnu skupinu; i, R2, R3, R4, Z', Q i W' mogu imati jednu ili više zaštitnih skupina, potrebnih u sintezi.
The compound for use according to claim 2, wherein the tumor disease is a solid tumor, preferably an epithelial tumor. The compound for use according to claim 3, wherein the epithelial tumor is prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, kidney cancer; thyroid carcinoma; uterine carcinoma; or adrenal carcinoma. 
Spoj, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 7 ili 8, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poželjnije gdje su tumori epitela karcinom prostate; karcinom dojke; karcinom gušterače; karcinom pluća; karcinom gastrointestinalnog sustava, poput karcinoma debelog crijeva; rak bubrega; karcinom štitnjače; karcinom maternice; ili karcinom nadbubrežne žlijezde.
The aqueous agrochemical suspension formulation according to claim 6, wherein an amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 5 to 60 parts by weight, an amount of the inorganic thickener is within a range of 4 to 30 parts by weight and an amount of the dispersant is within a range of 5 to 85 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1 ili 6, gdje suspenzija je formulacija i količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 5 do 60 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 4 do 30 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 5 do 85 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.
Container (1) according to claim 8, wherein the first protrusion (8) is located above or in the broadest part of the casing (2) and/or the further protrusion (9) is located below or in that part. 
Spremnik (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva 2 ili 3, naznačen time što tijelo (2) i/ili oplata (5) ima dodatno obodno suženje, koje pozitivno ograničava tijelo u aksijalnom smjeru.
TGA indicated a weight loss of about 3.3647 % from ambient temperature to about 250 °C. 
TGA je prikazao gubitak težine od oko 3.3647 % od sobne temperature do oko 250"C.
an X-Ray Powder Diffraction (XRPD) pattern with peaks at 13.3, 16.1 and 19.2 degrees 2θ (± 0.1 degrees 2θ); and/or 
model rendgenske difrakcije praha (XRPD) sa vršnim tačkama na 13,3, 16,1 i 19,2 stupnjeva 2θ (± 0,1 stupanj 2θ); i/ili
In other embodiments, the skin disease or disorder is alopecia. In some embodiments, the alopecia is selected from baldness or drug-induced alopecia. 
Farmaceutski pripravak za uporabu prema zahtjevu 32, naznačen time da je kožna bolest ili poremećaj alopecija.
The method of claim 1, further comprising fusion-registration of (a) the at least one irradiated readout image with, (b) the at least one control readout image with, (c) at least one three-dimensional dose distribution calculated by the patient-specific radiotherapy treatment plan. 
Postupak prema patentom zahtjevu 1, naznačen time što korak kreiranja fuzije-registracije (a) i (b) nadalje sadrži fuziju-registraciju (c) najmanje jedne trodimenzionalne raspodjele doze koja je izračunata planom radioterapijskog liječenja.
Process according to paragraph 24, wherein the reaction is carried out in a mixture of organic solvent and water, particularly in a ratio of 10:1 to 1:10, preferably 8:1 to 1:3, more preferably 5:1 to 1:1, most preferably 4:1 to 2:1. Process according to paragraph 25, wherein the organic solvent is selected from acetonitrile, acetone, methanol, ethanol, isopropanol and mixtures thereof. 
Postupak prema zahtjevu 9, naznačen time, da se reakcija provodi u mješavini organskog otapala i vode, posebno u omjeru od 10:1 do 1:10, poželjno od 8:1 do 1:3, još bolje od 5:1 do 1:1, najbolje od 4:1 do 2:1, pri čemu je organsko otapalo poželjno odabrano od acetonitrila, acetona, metanola, etanola, izopropanolainjihovih mješavina.
Similar results have been obtained in experimental models of Huntington's disease (HD). 
Slični rezultati su dobiveni u eksperimentalnim modelima kod Huntingtonove bolesti (HB).
Alkylpolyglycosides are nonionic surfactants that can be obtained by reacting sugars and alcohols in accordance with relevant methods of preparative organic chemistry, the result being (depending on how they are manufactured) a mixture of monoalkylated, oligomeric, or polymeric sugars. 
masnih alkohola i karboksilnih kiselina, sarkozinati masnih kiselina, kokoamidopropilamin oksidi, aminopropionati i biosurfaktanti,- mirise i- vodu, naznačen time da sadrži ester jantarne kiseline poliizobutena kao promotor adhezije i koji ne sadrži daljnje promotore adhezije i surfaktante.
The receiving method according to claim 9, wherein the portion of the bits necessary to indicate the allocated plurality of clusters are LSBs (Least Significant Bits) of the resource allocation information. 
Postupak prijenosa prema zahtjevu 9, naznačen time da su dio bitova potrebnih za označavanje dodijeljenog pluraliteta klastera LSB-ovi, Najmanje Bitni Bitovi, podatka o dodjeli resursa.
the CH3 domain of the first heavy chain comprises a substitution of the amino acid residue at position 366 as compared to wildtype and according to the EU numbering system, by a positively charged amino acid residue, and the CH3 domain of the second heavy chain comprises substitutions of the amino acid residues at positions 349 and 351 and 355 as compared to wildtype and according to the EU numbering system, by negatively charged amino acid residues; or the CH3 domain of the first heavy chain comprises substitutions of the amino acids at positions 351 and 366 as compared to wildtype and according to the EU numbering system, by positively charged residues, and the CH3 domain of the second heavy chain comprises substitutions of the amino acid residues at positions 351 and 368 as compared to wildtype and according to the EU numbering system, by negatively charged amino acid residues; or 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što navedeni treći polipeptidni lanac koji sadrži CH3 domenu sadrži lizinski (K) ostatak na aminokiselinskom položaju 356 u skladu s EU sustavu numeracije i lizinski (K) ostatak na aminokiselinskom položaju 399 u skladu s EU sustavu numeracije, i navedeni četvrti polipeptidni lanac koji sadrži CH3 domenu sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 392 u skladu s EU sustavu numeracije i ostatak asparaginske kiseline (D) na aminokiselinskom položaju 409 u skladu s EU sustavu numeracije. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što svaki od polipeptidnih lanaca koji sadrže CH3 domenu dalje sadrži varijabilnu regiju koja prepoznaje ciljni epitop.
Method according to embodiment 7, wherein the scratch resistant particles are or comprise nanosized silica particles, preferably fused silica particles. 
Postupak prema jednom bilo kojem od prethodnih patentnih zahtjeva, naznačen time da čestice otporne na ogrebotine jesu ili sadrže čestice od silicijevog dioksida veličine nanometra, poželjno čestice od rastopljenog silicijevog dioksida.
Single substitutions in the heavy chain variable region that met these thresholds were the following: Y27H, I34H, L52H, and S57H, all relative to SEQ ID NO:7. See Figs. 
Izolirano antitijelo, ili njegov fragment koji se veže na antigen, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da sadržava konstantnu regiju teškog lanca prikazanu u SEQ ID NO: 13.
directing the feedstock stream to a first reaction zone where it is contacted with a metal carbonyl compound and at least a portion of the ethylene oxide is converted to a product stream comprising beta propiolactone; 
usmjeravanja struje sirovine u prvo područje reakcije gdje dolazi u kontakt s metalnim karbonilnim spojem i u najmanju ruku dio etilen-oksida se prevede u struju produkta koja sadrži B-propiolakton;
A process as claimed in claim 6, 7 or 8 wherein the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 2 to 4 bar. 
Postupak prema zahtjevu 11 naznačen time da se hidrogeniranje spoja formule (II) provodi pri tlaku od 2 do 4 bar.
3,11b- cis -dihydrotetrabenazine for use according to claim 3 wherein the 3,11b-cis-dihydrotetrabenazine is for use in the prophylactic treatment of a patient within the age range 15 - 50 years who is carrying the mutant form of the HD gene but who have not yet developed symptoms of the disease, the prophylactic treatment being for the purpose of preventing or slowing the onset of symptoms associated with Huntington's disease. 
Spoj za uporabu u skladu sa zahtjevom 3, naznačen time, da se spoj koristi za profilaktično liječenje pacijenata u rasponu dobi od 15-50 godina koji nose mutantni oblik HD gena, ali koji nisu još razvili simptome bolesti, a profilaktično se liječenje provodi u svrhu sprečavanja ili usporavanja nastupa simptoma povezanih s Huntingtonovom bolesti, pri čemu je spoj (+) izomer 3,1 1b-cis-dihidrotetrabenazina ili njegova farmaceutski prihvatljiva sol kako je određeno u zahtjevu 1.